News

The FDA revised its emergency use authorization for EVUSHELD™, tixagevimab co-packaged with cilgavimab.

The requirement is exacerbating problems that revenue cycles have been trying to solve for years, and the AHA is lobbying for changes.

A court ruling has invalidated HHS’ implementation of the independent dispute resolution process of the No Surprises Act.

The American Medical Association recently announced three new CPT codes for administration of Pfizer’s COVID-19 vaccine in children 6 months to under 5 years old.

CMS has recently published One-Time Notification Transmittal 11191 regarding the new codes for the Acute Hospital Care at Home program.

The new guidelines include updated tabular instructions and clarification on reporting codes for underimmunization for COVID-19.

CMS recently created a new Healthcare Common Procedure Coding System (HCPCS) code, J0248, for VEKLURY™ (remdesivir), an antiviral medication that is used to treat COVID-19.

NAHRI is partnering with a new testing partner for our Certification in Healthcare Revenue Integrity (CHRI), Prometric. Learn more about changes to the testing processing.

The deadline to apply to speak at the 2022 Revenue Integrity Symposium (RIS) has been extended to January 19.

The No Surprises Act’s independent dispute resolution process unfairly favors payers and should be overhauled, according to the American Hospital Association.